https://banglajol.info/index.php/IJH/issue/feedInternational Journal of Hepatology2010-11-29T07:39:04+00:00Dr Mamun-al-Mahtabshwapnil@agni.comOpen Journal Systems<p><span style="color: #221e1f;"><span style="color: #221e1f;">As far as we are aware, this journal is no longer being published.<br /></span></span></p><p><span style="color: #221e1f;"><span style="color: #221e1f;">Official Journal of Viral Hepatitis Foundation Bangladesh. <br />Formerly the <em>Bangladesh Liver Journal</em>. Full text articles available.<br /></span></span></p>https://banglajol.info/index.php/IJH/article/view/6568Hepatitis C in Pakistan- A neglected challenge2010-11-29T07:39:04+00:00Waris Qidwaiwaris.qidwai@aku.eduAmmad Fahimwaris.qidwai@aku.eduShahan Waheedwaris.qidwai@aku.edu<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.5-7Copyright (c) https://banglajol.info/index.php/IJH/article/view/6573Hepatitis C - Goals of therapy and monitoring of therapy2010-11-29T07:39:04+00:00Premashis Karpremashish_kar@rediffmail.comRajib Kishore Hazampremashish_kar@rediffmail.com<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.36-44Copyright (c) https://banglajol.info/index.php/IJH/article/view/6574NAFLD current concepts2010-11-29T07:39:04+00:00Deepak Amarapurkaramarapurkar@gmail.com<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.45-49Copyright (c) https://banglajol.info/index.php/IJH/article/view/6575Rationality and designing immune therapy against chronic hepatitis B virus infection2010-11-29T07:39:04+00:00Sheikh Mohammad Fazle Akbarsheikh.akbar@toshiba.co.jpMamun Al-Mahtabsheikh.akbar@toshiba.co.jpSakirul Islam Khansheikh.akbar@toshiba.co.jp<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.49-50Copyright (c) https://banglajol.info/index.php/IJH/article/view/6576Fibroscan: Non-invasive liver diagnostic device for detection of liver fibrosis2010-11-29T07:39:04+00:00Grace Lai-Hung Wongwonglaihung@gmail.com<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.50-52Copyright (c) https://banglajol.info/index.php/IJH/article/view/6571Association between non-alcoholic fatty liver disease and metabolic syndrome2010-11-29T07:39:04+00:00Rasheeta Sivapackianathantahseen.chowdhury@bartsandthelondon.nhs.ukArthur J Asivathamtahseen.chowdhury@bartsandthelondon.nhs.ukMamun Al-Mahtabtahseen.chowdhury@bartsandthelondon.nhs.ukTahseen A Chowdhurytahseen.chowdhury@bartsandthelondon.nhs.ukMetabolic syndrome describes the co-occurrence of central adiposity, dysglycaemia, hypertension, lipid abnormalities and a number of other metabolic changes that increase risk of cardiovascular disease. This multi-system condition has adverse effects on many organs, the liver being one of them. Non-alcoholic fatty liver disease appears to be the hepatic manifestation of metabolic syndrome, and is increasingly recognised as a major contributor to the burden of chronic liver disease world-wide. Metabolic syndrome and non-alcoholic fatty liver disease appear to have a common pathogenesis, arising from insulin resistance, central adiposity and chronic low grade inflammation. Treatment of metabolic syndrome may have a significant impact on progression of non-alcoholic fatty liver disease, and therapeutic options treating the underlying cause of metabolic syndrome (weight loss and insulin sensitising drug therapy) appear to be valid options in treating liver disease to prevent progression to fibrosis and cirrhosis. Recent studies suggest a possible role for vitamin E. Prevention of obesity is extremely important to reduce the risk of this condition leading to a growing cause of liver morbidity in the future. <br /><br /><strong>Keywords: </strong>Non-alcoholic steatohepatitis; non-alcoholic fatty liver disease; metabolic syndrome <br /><br /><em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.17-24Copyright (c) https://banglajol.info/index.php/IJH/article/view/6572Current and emerging treatments for cholangiocarcinoma2010-11-29T07:39:04+00:00Christopher Limfluppy888@yahoo.comDesmond Waifluppy888@yahoo.comKH Leefluppy888@yahoo.comKC Tanfluppy888@yahoo.comSurgical resection, the treatment of choice for cholangiocarcinoma, may not be feasible because of tumour extension, parenchymal liver disease or tumour location. Liver transplantation is an alternative to palliative treatment in these patients but results in the past have been disappointing. In this article, we review the current and emerging treatments for cholangiocarcinomas, focusing particularly on the role of neoadjuvant chemotherapy and/ or radiotherapy in the setting of liver transplantation. <br /><br /><strong>Keywords:</strong> Cholangiocarcinoma; biliary tract neoplasms; living donor liver transplantation; cadaveric donor liver transplantation. <br /><br /><em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.25-35Copyright (c) https://banglajol.info/index.php/IJH/article/view/6569LIVERCON 2010 at a Glance2010-11-29T07:39:04+00:00The Editorhbd@dhaka.net<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.8-12Copyright (c) https://banglajol.info/index.php/IJH/article/view/6570LIVERCON 2010: Abstracts2010-11-29T07:39:04+00:00The Editorhbd@dhaka.net<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.13-16Copyright (c) https://banglajol.info/index.php/IJH/article/view/6577Management of recurrent bleeding from facial arteriovenous malformations in end-stage liver disease2010-11-29T07:39:04+00:00Syed Sufyan Hussainshahid.khan@imperial.ac.ukKuldeep S Cheentshahid.khan@imperial.ac.ukShahid A Khanshahid.khan@imperial.ac.ukJames E Jacksonshahid.khan@imperial.ac.ukMary ME Crosseyshahid.khan@imperial.ac.ukHoward C Thomasshahid.khan@imperial.ac.ukSimon D Taylor Robinsonshahid.khan@imperial.ac.ukWe report the management by arterial embolisation of recurrent significant bleeding from a facial arteriovenous malformation (AVM) in a patient with end-stage liver disease. Given their propensity to re-bleed, AVMs are often refractory to other forms of treatment, including surgery. Evidence from the management of facial AVMs and our case suggests that embolisation may offer a better initial management strategy in patients with end-stage liver disease related facial AVMs. <br /><br /><em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.53-54Copyright (c)